Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Clinical Trial Details

This is an observational study for people with myelofibrosis (MF), lower risk or higher risk myelodysplastic syndromes (MDS), Idiopathic Cytopenia of Undetermined Significance (ICUS), and acute myeloid leukemia (AML).

In this study, participants will continue with their standard of care and any medications currently prescribed, and information will be collected relating to the standard medical care they are receiving.
The main purposes of this study are to use the information collected to help better understand patterns for diagnosis, treatment and outcomes, including disease progression, survival, and quality of life in these patient populations, and to use results of this study to provide information to help better understand the effect different treatments have on a patient’s disease and on their quality of life.

Participation is expected to last around 8 years.

Key Eligibility: 
  1. A confirmed diagnosis of Myelofibrosis (MF), Idiopathic Cytopenia of Undetermined Significance (ICUS), Lower Risk Myelodysplastic Syndromes (LR-MDS), Higher Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Detailed eligibility reviewed when participant contacts the study team.

Study contact by location

Upper East Side - Manhattan


Victoria Mendez

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:




Open to Enrollment

Age Group